Patient Demographics and Disease Characteristics
| Characteristics . | HD (n = 21) . | CTCL (n = 35) . | NHL (n = 17) . | All Patients (n = 73) . |
|---|---|---|---|---|
| Age, years | ||||
| Mean | 30.8 | 61.4 | 53.4 | 50.7 |
| (Range) | (16 to 60) | (40 to 81) | (20 to 71) | (16 to 81) |
| Sex | ||||
| M | 11 (52%) | 24 (69%) | 9 (53%) | 44 (60%) |
| F | 10 (48%) | 11 (31%) | 8 (47%) | 29 (40%) |
| Disease duration, (years) | ||||
| Mean | 2.9 | 3.6 | 4.8 | 3.7 |
| (Range) | (1.1 to 5.2) | (0.2 to 12) | (0.7 to 16.1) | (0.2 to 16.1) |
| Stage (Ann Arbor, CTCL) | ||||
| I | 1 (5%) | 8 (23%) | 0 (0%) | 9 (12%) |
| II | 6 (29%) | 10 (28%) | 1 (6%) | 17 (23%) |
| III | 4 (20%) | 7 (20%) | 6 (36%) | 17 (23%) |
| IV | 10 (48%) | 10 (28%) | 10 (59%) | 30 (41%) |
| Prior therapies | ||||
| Median | 4 | 3 | 4 | 4 |
| (Range) | (3 to 10) | (0 to 15) | (2 to 10) | (0 to 15) |
| Dose group | ||||
| 3-9 | 8 | 8 | 3 | 19 |
| 12-15 | 4 | 6 | 8 | 18 |
| 19 | 5 | 8 | 5 | 18 |
| 23-27 | 3 | 9 | 1 | 13 |
| 31 | 1 | 4 | 0 | 5 |
| Characteristics . | HD (n = 21) . | CTCL (n = 35) . | NHL (n = 17) . | All Patients (n = 73) . |
|---|---|---|---|---|
| Age, years | ||||
| Mean | 30.8 | 61.4 | 53.4 | 50.7 |
| (Range) | (16 to 60) | (40 to 81) | (20 to 71) | (16 to 81) |
| Sex | ||||
| M | 11 (52%) | 24 (69%) | 9 (53%) | 44 (60%) |
| F | 10 (48%) | 11 (31%) | 8 (47%) | 29 (40%) |
| Disease duration, (years) | ||||
| Mean | 2.9 | 3.6 | 4.8 | 3.7 |
| (Range) | (1.1 to 5.2) | (0.2 to 12) | (0.7 to 16.1) | (0.2 to 16.1) |
| Stage (Ann Arbor, CTCL) | ||||
| I | 1 (5%) | 8 (23%) | 0 (0%) | 9 (12%) |
| II | 6 (29%) | 10 (28%) | 1 (6%) | 17 (23%) |
| III | 4 (20%) | 7 (20%) | 6 (36%) | 17 (23%) |
| IV | 10 (48%) | 10 (28%) | 10 (59%) | 30 (41%) |
| Prior therapies | ||||
| Median | 4 | 3 | 4 | 4 |
| (Range) | (3 to 10) | (0 to 15) | (2 to 10) | (0 to 15) |
| Dose group | ||||
| 3-9 | 8 | 8 | 3 | 19 |
| 12-15 | 4 | 6 | 8 | 18 |
| 19 | 5 | 8 | 5 | 18 |
| 23-27 | 3 | 9 | 1 | 13 |
| 31 | 1 | 4 | 0 | 5 |